BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 25226447)

  • 1. Pretargeted Radioimmunotherapy of Prostate Cancer with an Anti-TROP-2×Anti-HSG Bispecific Antibody and a (177)Lu-Labeled Peptide.
    van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
    Cancer Biother Radiopharm; 2014 Oct; 29(8):323-9. PubMed ID: 25226447
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretargeted immuno-PET and radioimmunotherapy of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody.
    van Rij CM; Lütje S; Frielink C; Sharkey RM; Goldenberg DM; Franssen GM; McBride WJ; Rossi EA; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2013 Sep; 40(9):1377-83. PubMed ID: 23674207
    [TBL] [Abstract][Full Text] [Related]  

  • 3. α- Versus β-Emitting Radionuclides for Pretargeted Radioimmunotherapy of Carcinoembryonic Antigen-Expressing Human Colon Cancer Xenografts.
    Heskamp S; Hernandez R; Molkenboer-Kuenen JDM; Essler M; Bruchertseifer F; Morgenstern A; Steenbergen EJ; Cai W; Seidl C; McBride WJ; Goldenberg DM; Boerman OC
    J Nucl Med; 2017 Jun; 58(6):926-933. PubMed ID: 28232604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pretargeted immunoPET of prostate cancer with an anti-TROP-2 x anti-HSG bispecific antibody in mice with PC3 xenografts.
    van Rij CM; Frielink C; Goldenberg DM; Sharkey RM; Franssen GM; Lütje S; McBride WJ; Oyen WJ; Boerman OC
    Mol Imaging Biol; 2015 Feb; 17(1):94-101. PubMed ID: 25060065
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pretargeted radioimmunotherapy and SPECT imaging of peritoneal carcinomatosis using bioorthogonal click chemistry: probe selection and first proof-of-concept.
    Rondon A; Schmitt S; Briat A; Ty N; Maigne L; Quintana M; Membreno R; Zeglis BM; Navarro-Teulon I; Pouget JP; Chezal JM; Miot-Noirault E; Moreau E; Degoul F
    Theranostics; 2019; 9(22):6706-6718. PubMed ID: 31588245
    [No Abstract]   [Full Text] [Related]  

  • 6. Quantitative immuno-SPECT monitoring of pretargeted radioimmunotherapy with a bispecific antibody in an intraperitoneal nude mouse model of human colon cancer.
    Schoffelen R; van der Graaf WT; Sharkey RM; Franssen GM; McBride WJ; Chang CH; Bos DL; Goldenberg DM; Oyen WJ; Boerman OC
    J Nucl Med; 2012 Dec; 53(12):1926-32. PubMed ID: 23081995
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alpha radioimmunotherapy using
    Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
    Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Theranostic pretargeted radioimmunotherapy of colorectal cancer xenografts in mice using picomolar affinity ⁸⁶Y- or ¹⁷⁷Lu-DOTA-Bn binding scFv C825/GPA33 IgG bispecific immunoconjugates.
    Cheal SM; Xu H; Guo HF; Lee SG; Punzalan B; Chalasani S; Fung EK; Jungbluth A; Zanzonico PB; Carrasquillo JA; O'Donoghue J; Smith-Jones PM; Wittrup KD; Cheung NV; Larson SM
    Eur J Nucl Med Mol Imaging; 2016 May; 43(5):925-937. PubMed ID: 26596724
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive patient-specific dosimetry and individualized dosing of pretargeted radioimmunotherapy in patients with advanced colorectal cancer.
    Schoffelen R; Woliner-van der Weg W; Visser EP; Goldenberg DM; Sharkey RM; McBride WJ; Chang CH; Rossi EA; van der Graaf WT; Oyen WJ; Boerman OC
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1593-602. PubMed ID: 24643780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theranostic pretargeted radioimmunotherapy of internalizing solid tumor antigens in human tumor xenografts in mice: Curative treatment of HER2-positive breast carcinoma.
    Cheal SM; Xu H; Guo HF; Patel M; Punzalan B; Fung EK; Lee SG; Bell M; Singh M; Jungbluth AA; Zanzonico PB; Piersigilli A; Larson SM; Cheung NV
    Theranostics; 2018; 8(18):5106-5125. PubMed ID: 30429889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex.
    Cheal SM; Xu H; Guo HF; Zanzonico PB; Larson SM; Cheung NK
    Mol Cancer Ther; 2014 Jul; 13(7):1803-12. PubMed ID: 24944121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Curative Multicycle Radioimmunotherapy Monitored by Quantitative SPECT/CT-Based Theranostics, Using Bispecific Antibody Pretargeting Strategy in Colorectal Cancer.
    Cheal SM; Fung EK; Patel M; Xu H; Guo HF; Zanzonico PB; Monette S; Wittrup KD; Cheung NV; Larson SM
    J Nucl Med; 2017 Nov; 58(11):1735-1742. PubMed ID: 28705917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A new Tri-Fab bispecific antibody for pretargeting Trop-2-expressing epithelial cancers.
    Sharkey RM; van Rij CM; Karacay H; Rossi EA; Frielink C; Regino C; Cardillo TM; McBride WJ; Chang CH; Boerman OC; Goldenberg DM
    J Nucl Med; 2012 Oct; 53(10):1625-32. PubMed ID: 22952342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Beta emitters rhenium-188 and lutetium-177 are equally effective in radioimmunotherapy of HPV-positive experimental cervical cancer.
    Phaeton R; Jiang Z; Revskaya E; Fisher DR; Goldberg GL; Dadachova E
    Cancer Med; 2016 Jan; 5(1):9-16. PubMed ID: 26625938
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pretargeted radioimmunotherapy using anti-CD45 monoclonal antibodies to deliver radiation to murine hematolymphoid tissues and human myeloid leukemia.
    Pagel JM; Matthews DC; Kenoyer A; Hamlin DK; Wilbur DS; Fisher DR; Gopal AK; Lin Y; Saganic L; Appelbaum FR; Press OW
    Cancer Res; 2009 Jan; 69(1):185-92. PubMed ID: 19118002
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pretargeted 177Lu radioimmunotherapy of carcinoembryonic antigen-expressing human colonic tumors in mice.
    Schoffelen R; van der Graaf WT; Franssen G; Sharkey RM; Goldenberg DM; McBride WJ; Rossi EA; Eek A; Oyen WJ; Boerman OC
    J Nucl Med; 2010 Nov; 51(11):1780-7. PubMed ID: 21051650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pretargeted radioimmunotherapy (PRIT) for treatment of non-Hodgkin's lymphoma (NHL).
    Weiden PL; Breitz HB
    Crit Rev Oncol Hematol; 2001 Oct; 40(1):37-51. PubMed ID: 11578915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of 211At-PRIT and 211At-RIT of ovarian microtumors in a nude mouse model.
    Frost SH; Bäck T; Chouin N; Hultborn R; Jacobsson L; Elgqvist J; Jensen H; Albertsson P; Lindegren S
    Cancer Biother Radiopharm; 2013 Mar; 28(2):108-14. PubMed ID: 23230896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pretargeted dual-modality immuno-SPECT and near-infrared fluorescence imaging for image-guided surgery of prostate cancer.
    Lütje S; Rijpkema M; Goldenberg DM; van Rij CM; Sharkey RM; McBride WJ; Franssen GM; Frielink C; Helfrich W; Oyen WJ; Boerman OC
    Cancer Res; 2014 Nov; 74(21):6216-23. PubMed ID: 25252911
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.